Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047500 · ClinicalTrials.gov registry record · Phase 1
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
A Phase 1 study, sponsored by ImmunoGenesis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02047500: Clinical Trial Phase 1 study, sponsored by ImmunoGenesis.
NCT02047500 is a Phase 1 study that was terminated before completion, run by ImmunoGenesis. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02047500, a Phase 1 study, was terminated before completion, sponsored by ImmunoGenesis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Why NCT02047500 stopped before completion
NCT02047500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02047500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02047500 about?
NCT02047500 is a clinical study titled "Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer". This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenoc...
What is the current status of trial NCT02047500?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-01. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02047500?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), TH-302 (DRUG).
Who is sponsoring clinical trial NCT02047500?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02047500's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia